JP5767122B2 - 特定の癌の治療のためのｒｄｅａ１１９／ｂａｙ８６９７６６を含む組み合わせ医薬 - Google Patents

特定の癌の治療のためのｒｄｅａ１１９／ｂａｙ８６９７６６を含む組み合わせ医薬 Download PDF

Info

Publication number
JP5767122B2
JP5767122B2 JP2011554220A JP2011554220A JP5767122B2 JP 5767122 B2 JP5767122 B2 JP 5767122B2 JP 2011554220 A JP2011554220 A JP 2011554220A JP 2011554220 A JP2011554220 A JP 2011554220A JP 5767122 B2 JP5767122 B2 JP 5767122B2
Authority
JP
Japan
Prior art keywords
cancer
administration
disclosed
compounds
composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2011554220A
Other languages
English (en)
Japanese (ja)
Other versions
JP2012520321A (ja
JP2012520321A5 (https=
Inventor
エス．チャップマン マーク
エス．チャップマン マーク
Original Assignee
アルデア バイオサイエンシズ，インコーポレイティド
アルデア バイオサイエンシズ，インコーポレイティド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=42135921&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=JP5767122(B2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by アルデア バイオサイエンシズ，インコーポレイティド, アルデア バイオサイエンシズ，インコーポレイティド filed Critical アルデア バイオサイエンシズ，インコーポレイティド
Publication of JP2012520321A publication Critical patent/JP2012520321A/ja
Publication of JP2012520321A5 publication Critical patent/JP2012520321A5/ja
Application granted granted Critical
Publication of JP5767122B2 publication Critical patent/JP5767122B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/18—Sulfonamides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4188—1,3-Diazoles condensed with other heterocyclic ring systems, e.g. biotin, sorbinil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N5/00—Radiation therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pathology (AREA)
  • Radiology & Medical Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2011554220A 2009-03-11 2010-03-11 特定の癌の治療のためのｒｄｅａ１１９／ｂａｙ８６９７６６を含む組み合わせ医薬 Expired - Fee Related JP5767122B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US15940309P 2009-03-11 2009-03-11
US61/159,403 2009-03-11
PCT/US2010/027060 WO2010105110A1 (en) 2009-03-11 2010-03-11 Pharmaceutical combinations comprising rdea119/bay 869766 for the treatment of specific cancers

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2014180216A Division JP5911929B2 (ja) 2009-03-11 2014-09-04 特定の癌の治療のためのｒｄｅａ１１９／ｂａｙ８６９７６６を含む組み合わせ医薬

Publications (3)

Publication Number Publication Date
JP2012520321A JP2012520321A (ja) 2012-09-06
JP2012520321A5 JP2012520321A5 (https=) 2013-04-04
JP5767122B2 true JP5767122B2 (ja) 2015-08-19

Family

ID=42135921

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2011554220A Expired - Fee Related JP5767122B2 (ja) 2009-03-11 2010-03-11 特定の癌の治療のためのｒｄｅａ１１９／ｂａｙ８６９７６６を含む組み合わせ医薬
JP2014180216A Expired - Fee Related JP5911929B2 (ja) 2009-03-11 2014-09-04 特定の癌の治療のためのｒｄｅａ１１９／ｂａｙ８６９７６６を含む組み合わせ医薬

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2014180216A Expired - Fee Related JP5911929B2 (ja) 2009-03-11 2014-09-04 特定の癌の治療のためのｒｄｅａ１１９／ｂａｙ８６９７６６を含む組み合わせ医薬

Country Status (23)

Country Link
US (2) US8673876B2 (https=)
EP (1) EP2405908B1 (https=)
JP (2) JP5767122B2 (https=)
KR (1) KR20110132371A (https=)
CN (2) CN103948600A (https=)
AU (1) AU2010224044A1 (https=)
BR (1) BRPI1009448A2 (https=)
CA (2) CA2972379A1 (https=)
CL (1) CL2011002233A1 (https=)
CO (1) CO6430423A2 (https=)
CR (1) CR20110479A (https=)
CU (1) CU20110170A7 (https=)
DO (1) DOP2011000282A (https=)
EA (1) EA201101302A1 (https=)
EC (1) ECSP11011314A (https=)
HK (1) HK1199710A1 (https=)
IL (1) IL214749A0 (https=)
MA (1) MA33091B1 (https=)
MX (1) MX2011009498A (https=)
PE (1) PE20120105A1 (https=)
SG (1) SG174272A1 (https=)
TN (1) TN2011000455A1 (https=)
WO (1) WO2010105110A1 (https=)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7723477B2 (en) 2005-10-31 2010-05-25 Oncomed Pharmaceuticals, Inc. Compositions and methods for inhibiting Wnt-dependent solid tumor cell growth
SG190568A1 (en) 2008-09-26 2013-06-28 Oncomed Pharm Inc Frizzled-binding agents and uses thereof
TWI535445B (zh) 2010-01-12 2016-06-01 安可美德藥物股份有限公司 Ｗｎｔ拮抗劑及治療和篩選方法
WO2013001372A2 (en) * 2011-06-30 2013-01-03 University Of Oslo Methods and compositions for inhibition of activation of regulatory t cells
EP2788378A4 (en) * 2011-12-09 2015-09-09 Oncomed Pharm Inc COMBINATION THERAPY FOR CANCER TREATMENT
US20150265679A1 (en) 2012-11-02 2015-09-24 The United States Of America, As Represented By Secretary, Department Of Health And Human Services Method of reducing adverse effects in a cancer patient undregoing treatment with a mek inhibitor
AU2014212081A1 (en) 2013-02-04 2015-08-13 Oncomed Pharmaceuticals, Inc. Methods and monitoring of treatment with a Wnt pathway inhibitor
EP3043778B1 (en) * 2013-09-13 2017-09-06 Bayer Pharma Aktiengesellschaft Pharmaceutical compositions containing refametinib
EP2848246A1 (en) * 2013-09-13 2015-03-18 Bayer Pharma Aktiengesellschaft Pharmaceutical compositions containing refametinib
US20170114323A1 (en) 2014-06-19 2017-04-27 Whitehead Institute For Biomedical Research Uses of kinase inhibitors for inducing and maintaining pluripotency
US12371667B2 (en) 2021-05-13 2025-07-29 Washington University Enhanced methods for inducing and maintaining naive human pluripotent stem cells

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9925958D0 (en) * 1999-11-02 1999-12-29 Bundred Nigel J Therapeutic use
WO2002039958A2 (en) * 2000-11-03 2002-05-23 Tularik Inc. Combination therapy using pentafluorobenzenesulfonamides and antineoplastic agents
AU2002340139A1 (en) * 2001-10-09 2003-04-22 The University Of Cincinnati Inhibitors of the egf receptor for the treatment of thyroid cancer
KR20060022647A (ko) * 2003-04-25 2006-03-10 길리애드 사이언시즈, 인코포레이티드 키나아제 억제 포스포네이트 유사체
WO2006066267A2 (en) * 2004-12-17 2006-06-22 Smithkline Beecham (Cork) Limited Cancer treatment method
WO2006076463A2 (en) * 2005-01-12 2006-07-20 Amgen Inc. Kinase-directed, activity-based probes
JP5106098B2 (ja) * 2005-02-28 2012-12-26 エーザイ・アール・アンド・ディー・マネジメント株式会社 スルホンアミド化合物の抗癌剤との新規併用
CA2618218C (en) * 2005-07-21 2015-06-30 Ardea Biosciences, Inc. N-(arylamino)-sulfonamide inhibitors of mek
US8101799B2 (en) * 2005-07-21 2012-01-24 Ardea Biosciences Derivatives of N-(arylamino) sulfonamides as inhibitors of MEK
US8329421B2 (en) 2007-07-13 2012-12-11 Ventana Medical Systems, Inc. Methods of predicting response of a neoplasm to an EGFR inhibitor and detecting interactions between EGFR and an EGFR regulatory protein
EA032294B1 (ru) 2007-07-30 2019-05-31 Арди Байосайенсиз, Инк. Способ получения полиморфной формы производного n-(ариламино)сульфонамида, фармацевтическая композиция, содержащая указанное производное, и способ лечения с помощью указанного производного
CA2924436A1 (en) * 2007-07-30 2009-02-05 Ardea Biosciences, Inc. Pharmaceutical combinations of n-(3,4-difluoro-2-(2-fluoro-4-iodophenylamino)-6-methoxyphenyl)-1-(2,3-dihydroxypropyl)cyclopropane-1-sulfonamide as inhibitors of mek and methods of use
US8044240B2 (en) * 2008-03-06 2011-10-25 Ardea Biosciences Inc. Polymorphic form of N-(S)-(3,4-difluoro-2-(2-fluoro-4-iodophenylamino)-6-methoxyphenyl)-1-(2,3-dihydroxypropyl)cyclopropane-1-sulfonamide and uses thereof
DE102008031039A1 (de) * 2008-06-30 2009-12-31 Dömling, Alexander, Priv.-Doz. Dr. Tarceva zur Anwendung in der Organtransplantation.

Also Published As

Publication number Publication date
MX2011009498A (es) 2011-10-14
CA2754913C (en) 2017-08-22
DOP2011000282A (es) 2011-10-15
JP2014237716A (ja) 2014-12-18
CN102421427B (zh) 2013-11-06
HK1199710A1 (en) 2015-07-17
JP2012520321A (ja) 2012-09-06
CR20110479A (es) 2011-10-24
US20140080783A1 (en) 2014-03-20
KR20110132371A (ko) 2011-12-07
SG174272A1 (en) 2011-10-28
CA2754913A1 (en) 2010-09-16
CO6430423A2 (es) 2012-04-30
JP5911929B2 (ja) 2016-04-27
AU2010224044A1 (en) 2011-09-22
TN2011000455A1 (en) 2013-03-27
CU20110170A7 (es) 2012-06-21
WO2010105110A1 (en) 2010-09-16
CN102421427A (zh) 2012-04-18
CA2972379A1 (en) 2010-09-16
BRPI1009448A2 (pt) 2016-03-01
CL2011002233A1 (es) 2012-02-03
IL214749A0 (en) 2011-11-30
ECSP11011314A (es) 2011-10-31
MA33091B1 (fr) 2012-03-01
EP2405908B1 (en) 2016-12-21
HK1169603A1 (en) 2013-02-01
US8673876B2 (en) 2014-03-18
US9220696B2 (en) 2015-12-29
US20120071435A1 (en) 2012-03-22
PE20120105A1 (es) 2012-02-22
EA201101302A1 (ru) 2012-05-30
CN103948600A (zh) 2014-07-30
EP2405908A1 (en) 2012-01-18

Similar Documents

Publication Publication Date Title
JP5911929B2 (ja) 特定の癌の治療のためのｒｄｅａ１１９／ｂａｙ８６９７６６を含む組み合わせ医薬
US20170157134A1 (en) Combination therapy
JP2012500180A5 (https=)
AU2927999A (en) Use of epothilones for the treatment of cancer
JP2019515909A (ja) 慢性リンパ性白血病の治療を目的とするｈｄａｃ阻害剤単独またはｂｔｋ阻害剤との配合物
JP5514123B2 (ja) 卵巣癌を治療するための、パクリタキセルを含む配合剤
CN111035640A (zh) 喹啉衍生物用于治疗甲状腺癌的方法和用途
RU2013154355A (ru) Способ лечения мезотелиомы ингибитором рi3к
TW201817425A (zh) 用於治療非酒精性脂肪肝疾病之醫藥組成物及方法
WO2004081012A1 (ja) 抗腫瘍効果増強剤及び抗腫瘍剤
JP2007500240A5 (https=)
JP2007500240A (ja) Ａｂｔ−７５１による持続投与レジメン
KR20050121324A (ko) 데커신 및/또는 데커시놀 안젤레이트, 또는 데커신및/또는 데커시놀 안젤레이트를 유효성분으로 하는당귀추출물을 포함하는 배뇨장애 치료제 및 부종 치료제조성물
WO2019242688A1 (zh) 3-羟基氨基苯甲酸与索拉非尼联合用药治疗肿瘤
JP2021533107A (ja) 癌を治療するための併用療法
HK1169603B (en) Pharmaceutical combinations comprising rdea119/bay 869766 for the treatment of specific cancers
CN121695138A (zh) 一类n-取代苯基-2-吡啶酮化合物在治疗癌症中的应用
JP2005507410A (ja) Ｂｃｒ／ａｂｌキナーゼ活性のＡＴＰ競合的阻害剤とチロホスチンアナログとの組合せ剤
JP2005520806A (ja) がん治療を改善する併用療法におけるキナゾリノン化合物
KR20070108941A (ko) 간암의 치료방법

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20130218

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20130218

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20140304

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20140603

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20140610

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20140904

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20141104

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20150203

RD03 Notification of appointment of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7423

Effective date: 20150317

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20150317

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20150317

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20150602

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20150618

R150 Certificate of patent or registration of utility model

Ref document number: 5767122

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

RD02 Notification of acceptance of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: R3D02

LAPS Cancellation because of no payment of annual fees